CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM

肠道 CYP3A 对咪达唑仑首过代谢的贡献

• 批准号: 6117753
• 负责人: D CRAIG BRATER
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117753
• 关键词: clarithromycin; clinical research; cytochrome P450; drug metabolism; human subject; intravenous administration; midazolam; oral administration; pharmacokinetics

A goal of this study is to determine the contribution of intestinal cytochrome P450 3A to the observed first-pass metabolism of midazolam following oral administration using silmultaneous intravenous and oral administration of midazolam and a stable isotope (N-midazolam). A second goal of the study is to determine if clarithromycin inhibits the metabolism of midazolam following oral administration at the intestinal or hepatic level.

这项研究的目标是确定肠的贡献 细胞色素P450 3A到观察到的咪达唑仑的第一频繁代谢 在口服静脉内和口服口服后进行口服给药 咪达唑仑和稳定的同位素（N-米达唑仑）的给药。 第二 该研究的目标是确定克拉霉素是否抑制 口服在肠道上给药后的代谢 肝水平。